Literature DB >> 35489731

The Systemic Inflammation Score Is an Independent Prognostic Factor for Esophageal Cancer Patients who Receive Curative Treatment.

Toru Aoyama1, Mihwa Ju2, Keisuke Komori2, Hiroshi Tamagawa2, Ayako Tamagawa2, Yukio Maezawa2, Itaru Hashimoto2, Kazuki Kano2, Kentaro Hara2,3, Haruhiko Cho2,3, Kenki Segami2, Daisuke Machida2, Masato Nakazono2, Takashi Oshima2,4, Norio Yukawa2, Yasushi Rino2.   

Abstract

BACKGROUND/AIM: Perioperative systemic inflammation affects the long-term oncological outcomes in cases of malignancies. We evaluated the clinical impact of the preoperative systemic inflammation score (SIS) in resectable esophageal cancer patients who received curative treatment. PATIENTS AND METHODS: This study included 168 patients who underwent curative surgery followed by perioperative adjuvant chemotherapy for esophageal cancer between 2005 and 2018. The risk factors for overall survival (OS) and recurrence-free survival (RFS) were identified.
RESULTS: Based on the 3- and 5-year OS rate, we set the cut-off value for SIS at 2 in the preset study. Among the 168 total patients, 119 were categorized as the Low-SIS group, and 49 were categorized as the High-SIS group. The respective 3- and 5-year OS rates were 61.9% and 52.4% in the Low-SIS group and 33.3% and 26.6% in the High-SIS group. There were significant differences in OS (p<0.001). The SIS was therefore selected for the final multivariate analysis model (hazard ratio=2.094, 95% confidence interval=1.355-3.234, p<0.001). On comparing the perioperative clinical course between the High- and Low-SIS groups, there were significant differences in the rate of postoperative anastomosis leakage of grade ≥2 between the groups (61.5% in the High-SIS group vs. 30.3% in the Low-SIS group; p=0.021).
CONCLUSION: The systemic inflammation score had a clinical effect on the long-term oncological outcomes in esophageal cancer patients, suggesting that it might be a promising prognostic factor for esophageal cancer patients.
Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Esophageal cancer; curative surgery; prognostic factor; systemic inflammation score

Mesh:

Year:  2022        PMID: 35489731     DOI: 10.21873/anticanres.15749

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  1 in total

1.  Albumin and Neutrophil-to-Lymphocyte Ratio Score in Neoadjuvant Concurrent Chemoradiotherapy for Esophageal Cancer: Comparison With Prognostic Nutritional Index.

Authors:  William Harrison Hsueh; Shun-Wen Hsueh; Kun-Yun Yeh; Yu-Shin Hung; Ming-Mo Ho; Shinn-Yn Lin; Chen-Kan Tseng; Chia-Yen Hung; Wen-Chi Chou
Journal:  In Vivo       Date:  2022 Sep-Oct       Impact factor: 2.406

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.